Novel Combo for Schizophrenia Succeeds in Phase III Trial

(MedPage Today) -- NEW ORLEANS--The investigational combination xanomeline-trospium (KarXT) succeeded in improving positive and negative symptoms of schizophrenia in the phase III EMERGENT-2 trial.
Meeting its primary endpoint, inpatients...